[HTML][HTML] Development of asciminib, a novel allosteric inhibitor of BCR-ABL1
D Réa, TP Hughes - Critical Reviews in Oncology/Hematology, 2022 - Elsevier
Chronic myeloid leukemia (CML) is driven by a translocation event between chromosomes 9
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1
D Réa, TP Hughes - Critical Reviews in Oncology …, 2022 - research.sahmri.org.au
Chronic myeloid leukemia (CML) is driven by a translocation event between chromosomes 9
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1
D Réa, TP Hughes - Critical reviews in oncology …, 2022 - pubmed.ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) is driven by a translocation event between chromosomes 9
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
D Réa, TP Hughes - Critical Reviews in Oncology/hematology, 2022 - europepmc.org
Chronic myeloid leukemia (CML) is driven by a translocation event between chromosomes 9
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …
and 22, leading to the formation of a constitutively active BCR-ABL1 oncoprotein. Approved …